Meningococcal B vaccination coverage among older adolescents in the United States

La, Elizabeth M.; Garbinsky, Diana; Hunter, Shannon; Poston, Sara; Novy, Patricia; Ghaswalla, Parinaz

doi:10.1016/j.vaccine.2021.03.071

Cited by 10 publications

(15 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in line with results from a prior study of the IBM MarketScan Commercial Claims and Encounters Database and MarketScan Multi-State Medicaid Database, 15 which examined individuals who initiated a MenB vaccine series during 2015 to 2016 (58% and 44% series completion, respectively) and those from a study that used 2017 to 2018 National Immunization Survey Teen data (47% series completion overall). 18 In the current study, individuals who received the first dose of MenB-4C were significantly more likely to complete the series than those who received the first dose of MenB-FHbp (Commercial: 61.1% versus 49.8%; Medicaid: 47.8% versus 33.9%), and this relationship persisted after adjustment in Poisson regression models. Furthermore, due to the differences in schedule recommendations, time to series completion was significantly shorter with MenB-4C than MenB-FHbp, resulting in earlier maximum protection with MenB-4C.…”

Section: Discussionmentioning

confidence: 51%

A Real-world Claims Data Analysis of Meningococcal Serogroup B Vaccine Series Completion and Potential Missed Opportunities in the United States

Packnett

Zimmerman

Kim

et al. 2022

Pediatric Infectious Disease Journal

Self Cite

View full text Add to dashboard Cite

Background: In the United States, meningococcal serogroup B (MenB) vaccination is recommended for 16-23-year-olds based on shared clinical decision-making. We estimated series completion among individuals initiating MenB vaccination for the 2 available vaccines: MenB 4-component (MenB-4C, doses at 0 and ≥1 month) and MenB factor H binding protein (MenB-FHbp, doses at 0 and 6 months). Methods: This retrospective health insurance claims data analysis included 16-23-year-olds who initiated MenB vaccination (index date) during January 2017 to November 2018 (MarketScan Commercial Claims and Encounters Database) or January 2017 to September 2018 (MarketScan Multi-State Medicaid Database) and had continuous enrollment for ≥6 months before and ≥15 months after index. The main outcome was MenB vaccine series completion within 15 months. Among noncompleters, preventive care/wellchild and vaccine administrative office visits were identified as potential missed opportunities for series completion. Robust Poisson regression models identified independent predictors of series completion. Results: In the Commercial (n = 156,080) and Medicaid (n = 57,082) populations, series completion was 56.7% and 44.7%, respectively, and was higher among those who initiated MenB-4C versus MenB-FHbp (61.1% versus 49.8% and 47.8% versus 33.9%, respectively; both P < 0.001). Among noncompleters, 40.2% and 34.7% of the Commercial and Medicaid populations, respectively, had ≥1 missed opportunity for series completion. Receipt of MenB-4C and younger age were independently associated with a higher probability of series completion. Conclusions: Series completion rates were suboptimal but were higher among those who initiated MenB-4C. To maximize the benefits of MenB vaccination, interventions to improve completion and reduce missed opportunities should be implemented.

show abstract

Section: Discussionmentioning

confidence: 51%

A Real-world Claims Data Analysis of Meningococcal Serogroup B Vaccine Series Completion and Potential Missed Opportunities in the United States

Packnett

Zimmerman

Kim

et al. 2022

Pediatric Infectious Disease Journal

Self Cite

View full text Add to dashboard Cite

show abstract

“…Results from this review showed variations by race/ethnicity in MenACWY [ 18 , 20 , 29 , 30 , 31 ] and MenB [ 32 , 33 , 34 , 35 ] vaccine coverage ( Supplementary Table S6 ).…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…A total of four studies have estimated differences in coverage of the MenB vaccine between non-Hispanic Black and White adolescents [ 32 , 33 , 34 , 35 ]. La et al [ 32 ] utilized a cross-sectional, retrospective, exploratory analysis of preexisting 2017–2018 NIS-Teen survey data on 7288 US individuals aged 17 years. The authors estimated unadjusted values for overall percent coverage of 16.1% for non-Hispanic Black persons and 13.5% for non-Hispanic White persons for ≥one dose of MenB vaccine.…”

Section: Resultsmentioning

confidence: 99%

“…A total of two studies presented estimates of differences in coverage of MenB vaccine by region of residence [ 32 , 33 ]. La et al [ 32 ] used 2017–2018 NIS-Teen survey data and determined that unadjusted coverage rates were highest in the Northeast region (18.3% for ≥one dose and 9.3% for ≥two doses) and lowest in the South region (14.6% for ≥one dose and 6.3% for ≥two doses); however, in all regions, estimated coverages were higher than that for New England in the multivariate analyses, with an adjusted OR of 1.90 (95% CI, 1.24–2.92) for the South Atlantic and 1.64 (95% CI, 1.03–2.62) for the Mountain region. In the study by Packnett et al [ 33 ], regional data were available only for the portion of the population with commercial insurance.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

The Impact of Social Determinants of Health on Meningococcal Vaccination Awareness, Delivery, and Coverage in Adolescents and Young Adults in the United States: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Vaccines remain a fundamental intervention for preventing illness and death. In the United States, suboptimal vaccine uptake in adolescents and young adults has been observed for meningococcal conjugate (MenACWY) and serogroup B meningococcal (MenB) vaccines, particularly among marginalized communities, despite current recommendations by the Advisory Committee on Immunization Practices. A systematic literature search was conducted in the MEDLINE and MEDLINE In-Process, Embase, Cochrane, PsychInfo, and CINAHL databases to identify both drivers of, and barriers to, MenACWY and MenB vaccine uptake in adolescents and young adults. A total of 34 of 46 eligible studies that presented outcomes stratified by race/ethnicity, geography, and socioeconomic status were selected for review. Results showed MenACWY and MenB vaccination coverage in adolescents and young adults is impacted by racial/ethnic, socioeconomic, and geographic disparities. Gaps also exist in insurance for, or access to, these vaccines in adolescents and young adults. Moreover, there was variability in the understanding and implementation of the shared decision-making recommendations for the MenB vaccine. Disease awareness campaigns, increased clarity in accessing all meningococcal vaccines, and further research on the relationships between measures of marginalization and its impact on vaccine coverage in adolescents and young adults are needed to reduce the incidence of severe infections.

show abstract

Determinants of Meningococcal Vaccination Coverage and Adherence: A Targeted Literature Review Supporting a 16-year-old Healthcare Visit

et al. 2023

View full text Add to dashboard Cite

We conducted a targeted literature review to understand the determinants of meningococcal serogroups A, C, W, and Y (MenACWY) and meningococcal serogroup B (MenB) vaccination coverage and adherence to vaccination schedules in the USA, and to identify evidence to support improvement of MenACWY and MenB vaccination coverage and adherence in older adolescents. Sources published since 2011 were considered, with sources published since 2015 given preference. Out of 2355 citations screened, 47 (46 studies) were selected for inclusion. Determinants of coverage and adherence ranging from patient-level sociodemographic factors to policy-level factors were identified. Four determinants identified were associated with improved coverage and adherence: (1) well-child, preventive, or vaccination-only appointments (particularly for older adolescents); (2) provider-initiated, provider-driven vaccine recommendations; (3) provider education about meningococcal disease and vaccine recommendations; and (4) state-level school-entry immunization policies. This robust review of the literature sheds light on the continued low MenACWY and MenB vaccination coverage and adherence among older adolescents (16–23 years of age) compared with that of younger adolescents (11–15 years of age) in the USA. The evidence supports a renewed call to action by local and national health authorities and medical organizations urging healthcare professionals to implement a healthcare visit for 16-year-olds and focus on vaccination as a key component of the visit. Supplementary Information The online version contains supplementary material available at 10.1007/s40121-023-00793-2.

show abstract

Meningococcal B vaccination coverage among older adolescents in the United States

Cited by 10 publications

References 27 publications

A Real-world Claims Data Analysis of Meningococcal Serogroup B Vaccine Series Completion and Potential Missed Opportunities in the United States

A Real-world Claims Data Analysis of Meningococcal Serogroup B Vaccine Series Completion and Potential Missed Opportunities in the United States

The Impact of Social Determinants of Health on Meningococcal Vaccination Awareness, Delivery, and Coverage in Adolescents and Young Adults in the United States: A Systematic Review

Determinants of Meningococcal Vaccination Coverage and Adherence: A Targeted Literature Review Supporting a 16-year-old Healthcare Visit

Contact Info

Product

Resources

About